Adosopine: Difference between revisions

Adosopine
Names
	IUPAC name N-(5-Methyl-6,11-dioxobenzo[c][1]benzazepin-10-yl)acetamide
	Other names Adosupine
Identifiers
CAS Number	88124-26-9;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2103994;
ChemSpider	59096;
ECHA InfoCard	100.081.230
PubChem CID	65661;
UNII	OKB1O47Q6F;
CompTox Dashboard (EPA)	DTXSID50868995 ;
	InChI InChI=1S/C17H14N2O3/c1-10(20)18-13-8-5-7-12-15(13)16(21)11-6-3-4-9-14(11)19(2)17(12)22/h3-9H,1-2H3,(H,18,20) Key: KLSKLNWJEDXFSD-UHFFFAOYSA-N; InChI=1/C17H14N2O3/c1-10(20)18-13-8-5-7-12-15(13)16(21)11-6-3-4-9-14(11)19(2)17(12)22/h3-9H,1-2H3,(H,18,20) Key: KLSKLNWJEDXFSD-UHFFFAOYAV;
	SMILES CC(=O)NC1=CC=CC2=C1C(=O)C3=CC=CC=C3N(C2=O)C;
Properties
Chemical formula	C17H14N2O3
Molar mass	294.310 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Content deleted Content added

Inline

Revision as of 08:29, 22 November 2017

Adosopine is a dibenzoazepine drug that has been studied for the treatment of urinary incontinence.^[1]^[2]

^ Perico, A; Triolo, A; Viti, G; Mannucci, C; Caviglioli, G; Cocchini, A; Pestellini, V; Paoli, P; Dapporto, P (1994). "Synthesis, characterization, and analytical studies of adosupine, a potential new drug for urinary incontinence". Journal of pharmaceutical sciences. 83 (2): 137–42. doi:10.1002/jps.2600830206. PMID 8169779.
^ d'Aranno, V; Mancinelli, A; Manzini, S (1992). "Determination of the tricyclic compound adosupine and its three metabolites in plasma and brain of rat using high-performance liquid chromatography". Journal of Chromatography. 574 (2): 319–25. doi:10.1016/0378-4347(92)80046-s. PMID 1618966.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

@@ Line 10: / Line 10: @@
 | ChemSpiderID = 59096
 | ChEMBL = 2103994
+| UNII = OKB1O47Q6F
 | InChI = 1/C17H14N2O3/c1-10(20)18-13-8-5-7-12-15(13)16(21)11-6-3-4-9-14(11)19(2)17(12)22/h3-9H,1-2H3,(H,18,20)
 | InChIKey = KLSKLNWJEDXFSD-UHFFFAOYAV
@@ Line 36: / Line 37: @@
-{{organic-compound-stub}}
+{{genito-urinary-drug-stub}}
-{{pharma-stub}}